This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:



The price of hope: CAR-T therapy in pediatric leukemia

Credit: Pixabay/CC0 Public Domain

We stand at the crossroads of medical innovation, where cutting-edge scientific discoveries intersect with the resilience of the human body, providing hope to families grappling with a diagnosis of pediatric leukemia.

In an editorial paper, published in Oncoscience and titled "The price of hope: CAR-T therapy in pediatric leukemia," researcher Alex Hoover from the University of Minnesota Medical School's Division of Pediatric Blood and Marrow Transplantation discusses the chimeric antigen receptor T-cell (CAR-T) therapy tisagenlecleucel (tisa-cel)—a groundbreaking development in the treatment of B-cell lineage (B-ALL) (the most common childhood cancer).

Following the pivotal ELIANA trial, tisa-cel was approved in the United States for the treatment of refractory or second or greater relapse of B-ALL in patients under age 25.

This innovative therapy involves genetically modifying a patient's native T-cells— with the ability to kill and/or regulate infected or diseased cells—to express a receptor that targets . The tisa-cel product is specifically engineered to target CD19 on B-lineage cells and has shown promising results in a historically challenging relapsed and refractory population.

Credit: Impact Journals LLC

Upon its approval in 2017, Novartis priced tisa-cel at $475,000—a number that many health care systems and payers balked at initially—and in 2023 the price increased to $508,250. However, compared to more recently approved ex vivo gene therapies such as bluebird bio's Zynteglo for beta thalassemia priced at $2.8 million or Vertex Pharmaceuticals' Casgevy for at $2.2 million, the half-million dollar tisa-cel price tag is less staggering.

Importantly, the listed cost of these therapies includes only the product and does not include the health care cost for other necessary care including leukapheresis, chemotherapy administration and adverse event monitoring and management.

"Our team recently published an in-depth analysis of the comprehensive cost and utilization of commercial CAR-T therapy in pediatric B-ALL patients with commercial insurance in the United States," say Hoover.

More information: Alex Hoover, The price of hope: CAR-T therapy in pediatric leukemia, Oncoscience (2024). DOI: 10.18632/oncoscience.598

Provided by Impact Journals LLC
Citation: The price of hope: CAR-T therapy in pediatric leukemia (2024, May 20) retrieved 15 June 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Advancing treatment for B-cell acute lymphoblastic leukemia


Feedback to editors